Skip to Main Content

And then there were … oh, forget it: We’ve given up trying to count the number of CRISPR companies, but we can tell you that one more came out of stealth mode on Thursday. After a year spent wooing investors, hiring, and refining its plans, Mammoth Biosciences, co-founded by CRISPR developer Jennifer Doudna, is announcing its entry into the ever-more-crowded fields of diagnostics and genome-editing, and hoping to find a sweet spot at their intersection.

“Mammoth Biosciences is all about building a CRISPR-based platform for disease detection,” said CEO Trevor Martin, who got a Ph.D. in genetics and statistics from Stanford in 2016.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED